A Narrative Review of Statin-Induced Rhabdomyolysis: Molecular Mechanism, Risk Factors, and Management.

IF 2.2 Q2 HEALTH CARE SCIENCES & SERVICES

Drug, Healthcare and Patient Safety Pub Date : 2021-11-08 eCollection Date: 2021-01-01 DOI:10.2147/DHPS.S333738

Nisa Safitri, Maya Fadila Alaina, Dian Ayu Eka Pitaloka, Rizky Abdulah

{"title":"A Narrative Review of Statin-Induced Rhabdomyolysis: Molecular Mechanism, Risk Factors, and Management.","authors":"Nisa Safitri, Maya Fadila Alaina, Dian Ayu Eka Pitaloka, Rizky Abdulah","doi":"10.2147/DHPS.S333738","DOIUrl":null,"url":null,"abstract":"<p><p>Although statins are effective for treating hypercholesterolemia, they can have various side effects, including rhabdomyolysis, a potentially fatal condition. This review evaluated the incidence and underlying molecular mechanism of statin-induced rhabdomyolysis and analyzed its risk factors, prevention, and management. We focused on the clinical and randomized clinical trials of statin monotherapies and combinations with other drugs. The primary mechanism of statin therapy-induced rhabdomyolysis is believed to be a decrease in ubiquinone (coenzyme Q) produced by the HMG-CoA pathway. Additionally, different types of lipophilic and hydrophilic statins play a role in causing rhabdomyolysis. Although statin-induced rhabdomyolysis has a low incidence, there is no guarantee that patients will be free of this side effect. Rhabdomyolysis can be prevented by reducing the risk factors, such as using CYP3A4 inhibitors, using high-dose statins, and strenuous physical activities.</p>","PeriodicalId":11377,"journal":{"name":"Drug, Healthcare and Patient Safety","volume":"13 ","pages":"211-219"},"PeriodicalIF":2.2000,"publicationDate":"2021-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d7/52/dhps-13-211.PMC8593596.pdf","citationCount":"12","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug, Healthcare and Patient Safety","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/DHPS.S333738","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}

引用次数: 12

Abstract

Although statins are effective for treating hypercholesterolemia, they can have various side effects, including rhabdomyolysis, a potentially fatal condition. This review evaluated the incidence and underlying molecular mechanism of statin-induced rhabdomyolysis and analyzed its risk factors, prevention, and management. We focused on the clinical and randomized clinical trials of statin monotherapies and combinations with other drugs. The primary mechanism of statin therapy-induced rhabdomyolysis is believed to be a decrease in ubiquinone (coenzyme Q) produced by the HMG-CoA pathway. Additionally, different types of lipophilic and hydrophilic statins play a role in causing rhabdomyolysis. Although statin-induced rhabdomyolysis has a low incidence, there is no guarantee that patients will be free of this side effect. Rhabdomyolysis can be prevented by reducing the risk factors, such as using CYP3A4 inhibitors, using high-dose statins, and strenuous physical activities.

Abstract Image

查看原文本刊更多论文

他汀类药物诱导的横纹肌溶解:分子机制、危险因素和管理。

尽管他汀类药物对治疗高胆固醇血症是有效的，但它们可能有各种副作用，包括横纹肌溶解，这是一种潜在的致命疾病。本文综述了他汀类药物诱导横纹肌溶解的发生率和潜在的分子机制，并分析了其危险因素、预防和管理。我们关注他汀类药物单药治疗和与其他药物联合的临床和随机临床试验。他汀类药物治疗诱导横纹肌溶解的主要机制被认为是由HMG-CoA途径产生的泛醌(辅酶Q)的减少。此外，不同类型的亲脂和亲水他汀类药物在引起横纹肌溶解中起作用。虽然他汀类药物引起的横纹肌溶解发病率低，但不能保证患者不会有这种副作用。横纹肌溶解可以通过减少危险因素来预防，例如使用CYP3A4抑制剂，使用高剂量他汀类药物和剧烈的体育活动。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drug, Healthcare and Patient Safety HEALTH CARE SCIENCES & SERVICES-

CiteScore

4.10

自引率

0.00%

发文量

审稿时长

16 weeks